Protagonist Therapeutics shares tank after clinical hold placed on rusfertide Check out this morning's top movers from around Wall Street, compiled by The Fly.
HIGHER -
- Innate Pharma (IPHA) up 25% after AstraZeneca (AZN) presented results from the randomized COAST Phase 2 trial and informed the company that it plans to start a registrational study with monalizumab in combination with durvalumab in patients with unresectable, Stage III non-small cell lung cancer
- AbCellera (ABCL) up 15% after the FDA expanded the Emergency Use Authorization for bamlanivimab 700 mg administered with etesevimab to include post-exposure prophylaxis to prevent SARS-CoV-2 infection or symptomatic COVID-19
- BeiGene (BGNE) up 13% after announcing the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted an opinion recommending approval of Brukinsa for the treatment of adult patients with Waldenstrom's macroglobulinemia
- Invesco (IVZ) up 6% after the Wall Street Journal reported the company is in discussions to combine with State Street's (STT) asset management unit
UP AFTER EARNINGS -
DOWN AFTER EARNINGS -
- Manchester United (MANU) down 2%
LOWER -
- Protagonist Therapeutics (PTGX) down 56% after announcing the receipt of a verbal communication from the FDA that Protagonist's clinical studies for rusfertide, an investigational product candidate currently in development, have been placed on a clinical hold
- Take-Two Interactive (TTWO) down 1% after BMO Capital analyst Gerrick Johnson downgraded shares to Market Perform with a price target of $150, down from $225
- Offerpad Solutions (OPAD) down 17% as the stock price continues to be volatile amid popularity of the name among retail investors
Symbols:
IPHA ABCL IVZ BGNE - $385.26 /
+10.94 (+2.92%)
BPTS MANU PTGX OPAD - $20.17 /
+7.395 (+57.89%)
TTWO STT Keywords: Fly Intel, Wall Street, Top Stories, Stocks